Description: Consumer Reports sent a letter to Senate Judiciary Committee Members in support of four bipartisan bills, set for a vote in the Committee, to promote more competition for pharmaceutical drugs so consumers who need them can get them at more affordable prices. Three of the bills prohibit anti-competitive practices engaged in by brand-name drug manufacturers to prolong their ability to reap inflated monopoly profits by delaying or blocking competition from lower-priced generics. The fourth would commission a study to shed light on pharmacy benefit managers, or PBMs, the middlemen between drug companies and health insurers and hospitals, where conflicts of interest could be leading to inflated prices for patients. All four bills were approved by the Committee.